Alpha1-proteinase inhibitor

BIOLOGICAL4 trials

Sponsors

CSL Behring, Baxalta now part of Shire, Blessing Corporate Services, Inc

Conditions

Alpha 1-Antitrypsin DeficiencyAlpha1-antitrypsin DeficiencyAlpha1-proteinase Inhibitor DeficiencyCovid19EmphysemaHealthy VolunteersPneumonia, Viral

Phase 3

Aralast NP With Antiviral Treatment and Standard of Care Versus Antiviral Treatment With Standard of Care in Hospitalized Patients With Pneumonia and COVID-19 Infection

WithdrawnNCT04675086

Blessing Corporate Services, IncCovid19, Pneumonia, Viral

Start: 2021-01-31End: 2021-12-31Updated: 2020-12-21

Phase 4

Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency

CompletedNCT00261833

CSL BehringAlpha1-proteinase Inhibitor Deficiency, Emphysema

Start: 2006-03-31End: 2012-09-30Updated: 2015-01-19

Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1 (Human Alpha 1 - Proteinase Inhibitor)

CompletedNCT00396006

Baxalta now part of ShireAlpha 1-Antitrypsin Deficiency

Start: 2006-10-27End: 2007-12-14Updated: 2021-05-13

GLASSIA Infusion Rate Study

CompletedNCT01651351

Baxalta now part of ShireAlpha1-antitrypsin Deficiency, Healthy Volunteers

Start: 2012-07-31End: 2013-01-16Updated: 2021-05-25

Related Papers

Pharmacokinetics and Biochemical Efficacy of an α1-Proteinase Inhibitor (Aralast NP) in α1-Antitrypsin Deficiency: a Cross-Product Retrospective Comparability Analysis

Pulmonary Therapy2022-08-241 citations

The Effect of Alpha-1 Proteinase Inhibitor on Biomarkers of Elastin Degradation in Alpha-1 Antitrypsin Deficiency: An Analysis of the RAPID/RAPID Extension Trials

Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation2016-12-0561 citations

Increased proportion of slow decliners in patients with alpha-1 protease inhibitor (A<sub>1</sub>-PI) deficiency following treatment with A<sub>1</sub>-PI

2016-09-012 citations

Correlation between change in lung density and lung function parameters in treated alpha-1 protease inhibitor (A<sub>1</sub>-PI) deficiency

2016-09-011 citations

LATE-BREAKING ABSTRACT: Long-term efficacy of A<sub>1</sub>-PI therapy in RAPID and RAPID extension trials

2015-09-011 citations

Assessment of A<sub>1</sub>-PI dose-exposure and exposure-response relationships in patients with Alpha-1 antitrypsin inhibitor deficiency

2015-09-01

Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.

2015-05-27359 citations